Skip to main content
SpringerLink
Log in

Treatment of Seizures in Older Patients with Dementia

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The numbers of patients with dementia and patients with epilepsy are increasing in the global population. In fact, these two conditions are related, and it is estimated that at least 5–10% of seizures or epilepsy in older individuals (aged > 60 years) are caused by a neurodegenerative dementia. In the vast majority, one of the four following diseases is involved: Alzheimer’s disease, Lewy body dementia, frontotemporal dementia, or vascular dementia. These diseases cause, not only seizures or epilepsy in affected patients, but cognitive, behavioral, and motor disorders as well. As a result, the challenges of treating seizures in older patients with neurodegenerative disease go beyond the usual limitations associated with this age group (i.e., lower fluid compartment, lower protein binding, increased risk of drug–drug interactions) by imposing other issues and pitfalls. In this setting, the drug-related potential aggravation of neurodegenerative symptoms must be taken into account. As cognition is particularly vulnerable, the prescription of antiseizure medications in dementia must consider the potential neurocognitive impact and limit it as much as possible. Consequently, the choice of a treatment for seizures in this age group is even more demanding than in younger patients, and therefore more restricted. Based on current but limited evidence, it appears that second-generation antiseizure medications are more likely to be appropriate for the management of older patients with epilepsy with neurodegenerative disease given their more favorable pharmacokinetic profiles. Nevertheless, even newer antiseizure medications are not devoid of any risks, which can however be anticipated and corrected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019–30. https://doi.org/10.1016/S1474-4422(09)70240-6.

    Article  PubMed  Google Scholar 

  2. Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395(10225):735–48. https://doi.org/10.1016/S0140-6736(19)33064-8.

    Article  PubMed  Google Scholar 

  3. Tallis R, Hall G, Craig I, Dean A. How common are epileptic seizures in old age? Age Ageing. 1991;20(6):442–8. https://doi.org/10.1093/ageing/20.6.442.

    Article  CAS  PubMed  Google Scholar 

  4. Hesdorffer DC, Logroscino G, Benn EK, Katri N, Cascino G, Hauser WA. Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota. Neurology. 2011;76(1):23–7. https://doi.org/10.1212/WNL.0b013e318204a36a.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol. 2005;4(10):627–34. https://doi.org/10.1016/S1474-4422(05)70172-1.

    Article  PubMed  Google Scholar 

  6. GBD 2016 Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 [published correction appears in Lancet Neurol. 2019 May;18(5):e4]. Lancet Neurol. 2019;18(4):357–75. https://doi.org/10.1016/S1474-4422(18)30454-X.

  7. Faught E, Richman J, Martin R, et al. Incidence and prevalence of epilepsy among older U.S. Medicare beneficiaries. Neurology. 2012;78(7):448–53. https://doi.org/10.1212/WNL.0b013e3182477edc.

  8. Ip Q, Malone DC, Chong J, Harris RB, Labiner DM. An update on the prevalence and incidence of epilepsy among older adults. Epilepsy Res. 2018;139:107–12. https://doi.org/10.1016/j.eplepsyres.2017.11.022.

    Article  PubMed  Google Scholar 

  9. Beghi E, Giussani G. Aging and the epidemiology of epilepsy. Neuroepidemiology. 2018;51(3–4):216–23. https://doi.org/10.1159/000493484.

    Article  PubMed  Google Scholar 

  10. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106. https://doi.org/10.1016/S1474-4422(18)30403-4.

  11. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34(3):453–68. https://doi.org/10.1111/j.1528-1157.1993.tb02586.x.

    Article  CAS  PubMed  Google Scholar 

  12. Friedman D, Honig LS, Scarmeas N. Seizures and epilepsy in Alzheimer’s disease. CNS Neurosci Ther. 2012;18(4):285–94. https://doi.org/10.1111/j.1755-5949.2011.00251.x.

    Article  PubMed  Google Scholar 

  13. Stefan H. Epilepsy in the elderly: facts and challenges. Acta Neurol Scand. 2011;124(4):223–7. https://doi.org/10.1111/j.1600-0404.2010.01464.x.

    Article  CAS  PubMed  Google Scholar 

  14. Subota A, Pham T, Jetté N, Sauro K, Lorenzetti D, Holroyd-Leduc J. The association between dementia and epilepsy: a systematic review and meta-analysis. Epilepsia. 2017;58(6):962–72. https://doi.org/10.1111/epi.13744.

    Article  PubMed  Google Scholar 

  15. Sarkis RA, Dickerson BC, Cole AJ, Chemali ZN. Clinical and neurophysiologic characteristics of unprovoked seizures in patients diagnosed with dementia. J Neuropsychiatry Clin Neurosci. 2016;28(1):56–61. https://doi.org/10.1176/appi.neuropsych.15060143.

    Article  PubMed  Google Scholar 

  16. Dementia: not all about Alzheimer’s. Lancet. 2015;386(10004):1600. https://doi.org/10.1016/S0140-6736(15)00672-8.

  17. Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology. 1996;46(3):727–30. https://doi.org/10.1212/wnl.46.3.727.

    Article  CAS  PubMed  Google Scholar 

  18. Beagle AJ, Darwish SM, Ranasinghe KG, La AL, Karageorgiou E, Vossel KA. Relative incidence of seizures and myoclonus in Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia. J Alzheimers Dis. 2017;60(1):211–23. https://doi.org/10.3233/JAD-170031.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rao SC, Dove G, Cascino GD, Petersen RC. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav. 2009;14(1):118–20. https://doi.org/10.1016/j.yebeh.2008.08.012.

    Article  PubMed  Google Scholar 

  20. Cretin B, Blanc F, Gaultier C, Sellal F. Epileptic amnesic syndrome revealing Alzheimer’s disease. Epilepsy Res. 2012;102(3):206–9. https://doi.org/10.1016/j.eplepsyres.2012.08.002.

    Article  PubMed  Google Scholar 

  21. Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013;70(9):1158–66. https://doi.org/10.1001/jamaneurol.2013.136.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lozsadi DA, Larner AJ. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;22(2):121–4. https://doi.org/10.1159/000093664.

    Article  CAS  PubMed  Google Scholar 

  23. Cretin B, Sellal F, Philippi N, et al. Epileptic prodromal Alzheimer’s disease, a retrospective study of 13 new cases: expanding the spectrum of Alzheimer’s disease to an epileptic variant? J Alzheimers Dis. 2016;52(3):1125–33. https://doi.org/10.3233/JAD-150096.

    Article  PubMed  Google Scholar 

  24. Arnaldi D, Donniaquio A, Mattioli P, et al. Epilepsy in neurodegenerative dementias: a clinical, epidemiological, and EEG study. J Alzheimers Dis. 2020;74(3):865–74. https://doi.org/10.3233/JAD-191315.

    Article  PubMed  Google Scholar 

  25. DiFrancesco JC, Tremolizzo L, Polonia V, et al. Adult-onset epilepsy in presymptomatic Alzheimer’s disease: a retrospective study. J Alzheimers Dis. 2017;60(4):1267–74. https://doi.org/10.3233/JAD-170392.

    Article  CAS  PubMed  Google Scholar 

  26. Costa C, Romoli M, Liguori C, et al. Alzheimer’s disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiol Aging. 2019;73:61–7. https://doi.org/10.1016/j.neurobiolaging.2018.09.006.

    Article  CAS  PubMed  Google Scholar 

  27. Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer’s disease. Neurology. 1986;36(9):1226–30. https://doi.org/10.1212/wnl.36.9.1226.

    Article  CAS  PubMed  Google Scholar 

  28. Sherzai D, Losey T, Vega S, Sherzai A. Seizures and dementia in the elderly: nationwide inpatient sample 1999–2008. Epilepsy Behav. 2014;36:53–6. https://doi.org/10.1016/j.yebeh.2014.04.015.

    Article  PubMed  Google Scholar 

  29. Zelano J, Brigo F, Garcia-Patek S. Increased risk of epilepsy in patients registered in the Swedish Dementia Registry. Eur J Neurol. 2020;27(1):129–35. https://doi.org/10.1111/ene.14043.

    Article  CAS  PubMed  Google Scholar 

  30. Baker J, Libretto T, Henley W, Zeman A. The prevalence and clinical features of epileptic seizures in a memory clinic population. Seizure. 2019;71:83–92. https://doi.org/10.1016/j.seizure.2019.06.016.

    Article  PubMed  Google Scholar 

  31. Cretin B, Philippi N, Bousiges O, et al. Do we know how to diagnose epilepsy early in Alzheimer’s disease? Rev Neurol (Paris). 2017;173(6):374–80. https://doi.org/10.1016/j.neurol.2017.03.028.

    Article  CAS  PubMed  Google Scholar 

  32. Vöglein J, Ricard I, Noachtar S, et al. Seizures in Alzheimer’s disease are highly recurrent and associated with a poor disease course. J Neurol. 2020. https://doi.org/10.1007/s00415-020-09937-7.2020(Epub 2 Jun 2020).

    Article  PubMed  PubMed Central  Google Scholar 

  33. Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Seizures in patients with Alzheimer’s disease or vascular dementia: a population-based nested case-control analysis. Epilepsia. 2013;54(4):700–7. https://doi.org/10.1111/epi.12045.

    Article  CAS  PubMed  Google Scholar 

  34. Gasparini S, Ferlazzo E, Beghi E, et al. Epilepsy associated with Leukoaraiosis mainly affects temporal lobe: a casual or causal relationship? Epilepsy Res. 2015;109:1–8. https://doi.org/10.1016/j.eplepsyres.2014.10.012.

    Article  PubMed  Google Scholar 

  35. Johnson EL, Krauss GL, Lee AK, et al. Association between white matter hyperintensities, cortical volumes, and late-onset epilepsy. Neurology. 2019;92(9):e988–95. https://doi.org/10.1212/WNL.0000000000007010.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Choi H, Pack A, Elkind MS, Longstreth WT Jr, Ton TG, Onchiri F. Predictors of incident epilepsy in older adults: the Cardiovascular Health Study. Neurology. 2017;88(9):870–7. https://doi.org/10.1212/WNL.0000000000003662.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Cretin B, Philippi N, Dibitonto L, Blanc F. Epilepsy at the prodromal stages of neurodegenerative diseases. Geriatr Psychol Neuropsychiatr Vieil. 2017;15(1):75–82. https://doi.org/10.1684/pnv.2017.0652.

    Article  PubMed  Google Scholar 

  38. Ukai K, Watanabe M. Transient epileptic amnesia accompanied by prodromal symptoms of dementia with Lewy bodies: the second case report in the literature. Psychogeriatrics. 2019;19(6):622–3. https://doi.org/10.1111/psyg.12434.

    Article  PubMed  Google Scholar 

  39. Marawar R, Wakim N, Albin RL, Dodge H. Seizure occurrence and related mortality in dementia with Lewy bodies. Epilepsy Behav. 2020;111:107311. https://doi.org/10.1016/j.yebeh.2020.107311(Epub 18 Jul 2020).

    Article  PubMed  Google Scholar 

  40. Morris M, Sanchez PE, Verret L, et al. Network dysfunction in α-synuclein transgenic mice and human Lewy body dementia. Ann Clin Transl Neurol. 2015;2(11):1012–28. https://doi.org/10.1002/acn3.257.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672–82. https://doi.org/10.1016/S0140-6736(15)00461-4.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51(4):671–5. https://doi.org/10.1111/j.1528-1167.2009.02285.x.

    Article  PubMed  Google Scholar 

  43. Gaxatte C, Puisieux F, Derambure P. Does the epileptic threshold change with age? Psychol Neuropsychiatr Vieil. 2007;5(1):5–9. https://doi.org/10.1684/pnv.2007.0096.

    Article  Google Scholar 

  44. Romanelli MF, Morris JC, Ashkin K, Coben LA. Advanced Alzheimer’s disease is a risk factor for late-onset seizures. Arch Neurol. 1990;47(8):847–50. https://doi.org/10.1001/archneur.1990.00530080029006.

    Article  CAS  PubMed  Google Scholar 

  45. Mendez MF, Catanzaro P, Doss RC, Arguello R, Frey WH 2nd. Seizures in Alzheimer’s disease: clinicopathologic study. J Geriatr Psychiatry Neurol. 1994;7(4):230–3. https://doi.org/10.1177/089198879400700407.

    Article  CAS  PubMed  Google Scholar 

  46. Giorgi FS, Saccaro LF, Busceti CL, Biagioni F, Fornai F. Epilepsy and Alzheimer’s disease: potential mechanisms for an association. Brain Res Bull. 2020;160:107–20. https://doi.org/10.1016/j.brainresbull.2020.04.009.

    Article  CAS  PubMed  Google Scholar 

  47. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66(4):435–40. https://doi.org/10.1001/archneurol.2009.15.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67. https://doi.org/10.1016/S1474-4422(13)70044-9.

    Article  CAS  PubMed  Google Scholar 

  49. Lam AD, Deck G, Goldman A, Eskandar EN, Noebels J, Cole AJ. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer’s disease. Nat Med. 2017;23(6):678–80. https://doi.org/10.1038/nm.4330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Vossel KA, Ranasinghe KG, Beagle AJ, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease. Ann Neurol. 2016;80(6):858–70. https://doi.org/10.1002/ana.24794.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Roberson ED, Halabisky B, Yoo JW, et al. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci. 2011;31(2):700–11. https://doi.org/10.1523/JNEUROSCI.4152-10.2011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci USA. 2012;109(42):E2895–903. https://doi.org/10.1073/pnas.1121081109.

    Article  PubMed  Google Scholar 

  53. Noebels J. A perfect storm: converging paths of epilepsy and Alzheimer’s dementia intersect in the hippocampal formation. Epilepsia. 2011;52 Suppl. 1(Suppl. 1):39–46. https://doi.org/10.1111/j.1528-1167.2010.02909.x.

  54. Lin R, Jones NC, Kwan P. Unravelling the role of glycogen synthase kinase-3 in Alzheimer’s disease-related epileptic seizures. Int J Mol Sci. 2020;21(10):3676. https://doi.org/10.3390/ijms21103676.

    Article  CAS  PubMed Central  Google Scholar 

  55. Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci. 2016;17(12):777–92. https://doi.org/10.1038/nrn.2016.141.

    Article  CAS  PubMed  Google Scholar 

  56. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging [published correction appears in Lancet Neurol. 2013;12(6):532]. Lancet Neurol. 2013;12(5):483–97. https://doi.org/10.1016/S1474-4422(13)70060-7.

  57. Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11(3):157–65. https://doi.org/10.1038/nrneurol.2015.10.

    Article  PubMed  Google Scholar 

  58. Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain. 2007;130(Pt 2):535–47. https://doi.org/10.1093/brain/awl317.

    Article  PubMed  Google Scholar 

  59. Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol. 2013;244:11–21. https://doi.org/10.1016/j.expneurol.2011.09.033.

    Article  CAS  PubMed  Google Scholar 

  60. De Reuck J, Nagy E, Van Maele G. Seizures and epilepsy in patients with lacunar strokes. J Neurol Sci. 2007;263(1–2):75–8. https://doi.org/10.1016/j.jns.2007.06.004.

    Article  PubMed  Google Scholar 

  61. Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer’s disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol. 2016;15(9):934–43. https://doi.org/10.1016/S1474-4422(16)30029-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. van der Zande JJ, Gouw AA, van Steenoven I, Scheltens P, Stam CJ, Lemstra AW. EEG characteristics of dementia with Lewy bodies, Alzheimer’s disease and mixed pathology. Front Aging Neurosci. 2018;10:190. https://doi.org/10.3389/fnagi.2018.00190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. García-Cabrero AM, Guerrero-López R, Giráldez BG, et al. Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol Dis. 2013;58:200–8. https://doi.org/10.1016/j.nbd.2013.06.005.

    Article  CAS  PubMed  Google Scholar 

  64. Kuroda M, Matsuwaki T, Tanaka Y, Yamanouchi K, Nishihara M. Convulsive responses to seizure-inducible drugs are exacerbated in progranulin-deficient mice. NeuroReport. 2020;31(6):478–83. https://doi.org/10.1097/WNR.0000000000001425.

    Article  CAS  PubMed  Google Scholar 

  65. Vatsavayai SC, Yoon SJ, Gardner RC, et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016;139(Pt 12):3202–16. https://doi.org/10.1093/brain/aww250.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134(2):187–205. https://doi.org/10.1007/s00401-017-1709-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Desmarais P, Miville C, Milán-Tomás Á, et al. Age representation in antiepileptic drug trials: a systematic review and meta-analysis. Epilepsy Res. 2018;142:9–15. https://doi.org/10.1016/j.eplepsyres.2018.03.005.

    Article  CAS  PubMed  Google Scholar 

  68. Lezaic N, Gore G, Josephson CB, Wiebe S, Jetté N, Keezer MR. The medical treatment of epilepsy in the elderly: a systematic review and meta-analysis. Epilepsia. 2019;60(7):1325–40. https://doi.org/10.1111/epi.16068.

    Article  PubMed  Google Scholar 

  69. Lattanzi S, Trinka E, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta-analysis. Epilepsia. 2019;60(11):2245–54. https://doi.org/10.1111/epi.16366.

    Article  PubMed  Google Scholar 

  70. Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav. 2010;17(4):461–6. https://doi.org/10.1016/j.yebeh.2010.01.015.

    Article  PubMed  Google Scholar 

  71. Cretin B. Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer’s disease. Expert Opin Pharmacother. 2018;19(11):1201–9. https://doi.org/10.1080/14656566.2018.1496237.

    Article  CAS  PubMed  Google Scholar 

  72. Villanueva V, Giráldez BG, Toledo M, De Haan GJ, Cumbo E, Gambardella A, et al. Lacosamide monotherapy in clinical practice: a retrospective chart review. Acta Neurol Scand. 2018;138(3):186–94. https://doi.org/10.1111/ane.12920.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci USA. 2012;109(42):E2895–903. https://doi.org/10.1073/pnas.1121081109.

    Article  PubMed  Google Scholar 

  74. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74(3):467–74. https://doi.org/10.1016/j.neuron.2012.03.023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Arnold S, Laloyaux C, Schulz AL, Elmoufti S, Yates S, Fakhoury T. Long-term safety and efficacy of brivaracetam in adults with focal seizures: results from an open-label, multinational, follow-up trial. Epilepsy Res. 2020;166:106404. https://doi.org/10.1016/j.eplepsyres.2020.106404.

    Article  CAS  PubMed  Google Scholar 

  76. Nygaard HB, Kaufman AC, Sekine-Konno T, Huh LL, Going H, Feldman SJ, et al. Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model. Alzheimers Res Ther. 2015;7(1):25. https://doi.org/10.1186/s13195-015-0110-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Ferlazzo E, Gasparini S, Beghi E, et al. Epilepsy in cerebrovascular diseases: review of experimental and clinical data with meta-analysis of risk factors. Epilepsia. 2016;57(8):1205–14. https://doi.org/10.1111/epi.13448.

    Article  PubMed  Google Scholar 

  78. Brigo F, Lattanzi S, Zelano J, et al. Randomized controlled trials of antiepileptic drugs for the treatment of post-stroke seizures: a systematic review with network meta-analysis. Seizure. 2018;61:57–62. https://doi.org/10.1016/j.seizure.2018.08.001.

    Article  CAS  PubMed  Google Scholar 

  79. Liu J, Wang LN, Wu LY, Wang YP. Treatment of epilepsy for people with Alzheimer’s disease. Cochrane Database Syst Rev. 2018;12(12):CD011922. https://doi.org/10.1002/14651858.CD011922.pub3.

    Article  PubMed  Google Scholar 

  80. Cretin B, Blanc F. How does epilepsy impact the pharmacotherapeutic management of patients with dementia with Lewy bodies? Expert Opin Pharmacother. 2020;21(4):377–9. https://doi.org/10.1080/14656566.2019.1707185.

    Article  PubMed  Google Scholar 

  81. Lezaic N, Roussy J, Masson H, Jetté N, Keezer MR. Epilepsy in the elderly: unique challenges in an increasingly prevalent population. Epilepsy Behav. 2020;102:106724. https://doi.org/10.1016/j.yebeh.2019.106724.

    Article  PubMed  Google Scholar 

  82. Vu LC, Piccenna L, Kwan P, O’Brien TJ. New-onset epilepsy in the elderly. Br J Clin Pharmacol. 2018;84(10):2208–17. https://doi.org/10.1111/bcp.13653.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Wechsler RT, Radtke RA, Smith M, et al. Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy. Epilepsia. 2019;60(7):1341–52. https://doi.org/10.1111/epi.16069.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Safahani M, Aligholi H, Asadi-Pooya AA. Management of antiepileptic drug-induced nutrition-related adverse effects. Neurol Sci. 2020. https://doi.org/10.1007/s10072-020-04573-5(Epub 14 Jul 2020).

    Article  PubMed  Google Scholar 

  85. Zaccara G, Lattanzi S. Comorbidity between epilepsy and cardiac arrhythmias: implication for treatment. Epilepsy Behav. 2019;97:304–12. https://doi.org/10.1016/j.yebeh.2019.05.038.

    Article  PubMed  Google Scholar 

  86. Roberti R, Palleria C, Nesci V, et al. Pharmacokinetic considerations about antiseizure medications in the elderly. Expert Opin Drug Metab Toxicol. 2020. https://doi.org/10.1080/17425255.2020.1806236(Epub 6 Aug 2020).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Neuropsychology Unit, Neurology Department, CM2R (Memory Resource and Research Centre), University Hospital of Strasbourg, Strasbourg, France

    Benjamin Cretin

  2. CNRS, ICube Laboratory, UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, University of Strasbourg, Strasbourg, France

    Benjamin Cretin

  3. CMRR d’Alsace, Service de Neurologie des Hôpitaux, Universitaires de Strasbourg, Pôle Tête et Cou, 1 Avenue Molière, 67200, Strasbourg, France

    Benjamin Cretin

Authors
  1. Benjamin Cretin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Cretin.

Ethics declarations

Funding

No funding was received for the preparation of this article.

Conflict of interest

Benjamin Cretin reports fees and honorarium from UCB-Pharma, Eisai-Pharma, and Advicenne-Pharma.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Author contributions

BC designed and conceptualized study, analyzed the data, drafted the manuscript for intellectual content, and read and approved the final version of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cretin, B. Treatment of Seizures in Older Patients with Dementia. Drugs Aging 38, 181–192 (2021). https://doi.org/10.1007/s40266-020-00826-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-020-00826-2

Search

Navigation